Envision Pharma Group said Wednesday that it has acquired Alligent Biopharm Consulting LLC. Financial terms weren’t announced. The Halifax Group also invested. Stirling, New Jersey-based Alligent Biopharm provides strategic medical planning and program implementation for the medical affairs departments of biopharma organizations.
HORSHAM, United Kingdom–(BUSINESS WIRE)–Envision Pharma Group (“Envision”), an innovative, technology-enabled scientific communications company focused on the biopharma and medical device industries, announced today that it has acquired Alligent Biopharm Consulting LLC (“Alligent”). Alligent is a leading Medical Affairs agency that develops and delivers strategically-focused, integrated and aligned medical communications solutions to the biopharma industry. The deal was supported by the Halifax Group, a leading private equity firm which invests in health and biopharma services businesses, partnering with the Envision management team to provide the equity investment to facilitate the acquisition. Additional terms of the transaction were not disclosed.
Alligent’s core skill sets of medical strategy development and planning, allied program implementation and stakeholder support will complement Envision’s existing services of strategic data dissemination – including publication planning, consultancy, and market access communications – to provide global Medical Affairs Departments with compliant, strategically focused evidence communication programs. Underpinning its services, the expanded Envision Pharma Group will continue to provide its expansive client base with industry-leading technology including Datavision™, Visiontracker™, Clear™ and Medinfo™. Alligent’s two principals, Joe Kohles and David Thompson, will also be joining the Envision Pharma Leadership team.
Envision’s CEO, Brian Hepburn, commented, “The addition of Alligent to the Envision Pharma Group further cements our core tenet of becoming the leading international medical affairs agency. By acquiring Alligent, we are able to expand the capabilities we offer to medical affairs teams to ensure optimal evidence communication and ultimate product adoption based on scientific rigor.”
Messrs. Kohles and Thompson stated, “We are delighted to join the Envision Pharma Group. Our focus on medical strategy, coupled with Envision’s global presence and technology leadership position, offers the potential for us to expand and enrich our service breadth and offering to current and future clients alike. We look forward to joining the Group’s leadership team and contributing to the continued success of both Alligent and Envision.”
“The addition of the Alligent team is truly complimentary to the Envision Pharma group. We believe their combined capabilities will further enhance Envision’s ability to optimize the communication of complex scientific data on behalf of their clients, which will be of ultimate benefit to health care providers, payors and patients,” added Halifax principal Scott Plumridge.
Founded in 2001, Envision Pharma is an international, innovative global technology and scientific communication company serving pharmaceutical, biotechnology and medical device companies. Initially focusing on publication planning Envision has evolved to become a leading provider of evidence communication services encompassing all aspects of scientifically driven data dissemination activities required to support a successful access to market strategy for new biopharma compounds. This capability of the organization is further enhanced with industry-leading complementary technology solutions. Envision has grown steadily under consistent leadership across its three core business areas that include (i) Evidence Communication – including strategic publication planning, data dissemination services and market access communications; (ii) Technology Solutions – design, development, implementation and support of innovative and strategic management software for life sciences clients including publication planning and management (DatavisionTM), clearance approval (ClearTM), and activity request management (VisiontrackerTM); and (iii) Consulting Solutions – policy, process, compliance and guideline consultancy to life-science companies. Envision has eight offices, two in the United Kingdom – Horsham and London, four in the United States including offices in Philadelphia, PA; Southport, CT; Madison, NJ and Glastonbury, CT and two in Asia Pacific -Tokyo and Sydney . The company employs approximately 380 team members, including over 160 highly qualified and experienced in-house medical writers and a 65-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 19 of the top 20 pharmaceutical companies.
About the Alligent Group
Alligent was built to support the strategic and tactical needs of the medical director and currently provides strategic medical planning and program implementation for the medical affairs departments of a number of leading biopharma organizations. Based in Stirling, NJ, the company employs over 30 communications and scientific experts with extensive industry and agency experience, particularly within the area of oncology.
About The Halifax Group
The Halifax Group is a private equity firm that partners with managers and entrepreneurs to recapitalize and grow lower middle-market businesses across a variety of industries including health and wellness, infrastructure, business and government services, and franchising. The firm maintains offices in Washington, D.C.; Dallas, TX; and Raleigh, NC. For more information, please visit www.thehalifaxgroup.com.